“…Recently, interest in the medicinal properties of Cannabis sativa has resurged with the emergence of the eCB, offering not only new insights into the mechanisms underlying the therapeutic actions of cannabinoid-like molecules and phytocannabinoids but also novel molecular targets for the pharmacotherapy of pain [ 2 , 140 ]. Studies in animal models of acute pain showed that Δ9-THC, CBD, AEA, and synthetic cannabinoids such as CP55,940 and WIN 55,212-2 had antinociceptive actions [ 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 ]. In a model of chronic pain, AEA and cannabinoid ligands were effective treatments [ 147 , 149 , 150 , 151 , 152 ].…”